GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

Yossi Cohen*, Odit Gutwein, Osnat Garach-Jehoshua, Adina Bar-Haim, Abraham Kornberg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Abstract

In a comparison of gene expression profile in unsorted bone marrow (BM) samples from patients with multiple myeloma (MM), acute leukemia, and diffuse large B-cell lymphoma infiltrating the BM, the leading myeloma distinguishing gene was GPRC5D. This gene was highly expressed in BM samples from the 10 MM cases examined as opposed to minimal expression in samples from the eight cases with other hematological malignancies. Moreover, following antimyeloma treatment the expression of GPRC5D decreased several folds. The strong and selective expression of GPRC5D in MM cells makes this gene and its encoded surface protein as promising markers for monitoring the tumor load and hopefully also as targets for antimyeloma antibodies.

Original languageEnglish
Pages (from-to)348-351
Number of pages4
JournalHematology
Volume18
Issue number6
DOIs
StatePublished - Nov 2013

Keywords

  • Bone marrow
  • Contactless signature
  • Elotuzumab
  • GPRC5D
  • Gene expression profile
  • Leukemia
  • Myeloma
  • SLAMF7

Fingerprint

Dive into the research topics of 'GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells'. Together they form a unique fingerprint.

Cite this